PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Cortes, J. [1 ]
O'Connell, A. [2 ]
Shaik, M. N. [3 ]
Cesari, R. [4 ]
Abbattista, A. [4 ]
Woolfson, A. [5 ]
Pollyea, D. [6 ]
Savona, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Pfizer Oncol, Collegeville, PA USA
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Milan, Italy
[5] Pfizer Oncol, New York, NY USA
[6] Univ Colorado, Ctr Canc, Aurora, CO USA
[7] Tennessee Oncol, Nashville, TN USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P179
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [31] A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Ghanem, H.
    Kantarjian, H.
    Garcia-Manero, G.
    Ravandi, F.
    Faderl, S.
    Cortes, J. E.
    Reyes, A.
    O'Brien, S. M.
    Borthakur, G.
    Kadia, T. M.
    Burger, J. A.
    Konopleva, M.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML)
    Jabbour, E.
    Faderl, S.
    Ravandi, F.
    Konopleva, M.
    Verstovsek, S.
    Cortes, J.
    Wierda, W.
    Newsome, W. M.
    Yang, H.
    Kantarjian, H.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W. K. Hofmann
    G. Heil
    C. Zander
    S. Wiebe
    O. G. Ottmann
    L. Bergmann
    K. Hoeffken
    J. T. Fischer
    A. Knuth
    K. Kolbe
    H. J. Schmoll
    W. Langer
    M. Westerhausen
    C. B. Koelbel
    D. Hoelzer
    A. Ganser
    Annals of Hematology, 2004, 83 : 498 - 503
  • [34] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    Hofmann, WK
    Heil, G
    Zander, C
    Wiebe, S
    Ottmann, OG
    Bergmann, L
    Hoeffken, K
    Fischer, JT
    Knuth, A
    Kolbe, K
    Schmoll, HJ
    Langer, W
    Westerhausen, M
    Koelbel, CB
    Hoelzer, D
    Ganser, A
    ANNALS OF HEMATOLOGY, 2004, 83 (08) : 498 - 503
  • [35] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Burnett, Alan K.
    Milligan, Donald
    Prentice, Archie G.
    Goldstone, Anthony H.
    McMullin, Mary F.
    Hills, Robert K.
    Wheatley, Keith
    CANCER, 2007, 109 (06) : 1114 - 1124
  • [36] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
  • [37] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Bouligny, Ian M.
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Jain, Nitin
    Pemmaraju, Naveen
    Hammond, Danielle
    Chien, Kelly S.
    Takahashi, Koichi
    Issa, Ghayas C.
    Abbas, Hussein A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 735 - 736
  • [38] Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Chen, Y.
    Kantarjian, H.
    Garcia-Manero, G.
    Estrov, Z.
    Konopleva, M.
    Jabbour, E.
    Kadia, T. M.
    Williams, E.
    George, S.
    Borthakur, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
  • [40] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Jorge E. Cortes
    Florian H. Heidel
    Andrzej Hellmann
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Daniel A. Pollyea
    Pierre DesJardins
    Oliver Ottmann
    Weidong Wendy Ma
    M. Naveed Shaik
    A. Douglas Laird
    Mirjana Zeremski
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Leukemia, 2019, 33 : 379 - 389
12345